Our results showed significant synergistic therapeutic effects of shikonin (an inhibitor of Pkm2) and ZM 336372 (an inhibitor of Raf1) in Hepa1‐6 cells and the four HCC cell lines (Figure 5D, F, H and J and S7E). The gene discussed is PKM; the disease is hepatocellular carcinoma.